Expression of the Ets-1 proto-oncogene in melanocytic lesions

被引:21
|
作者
Keehn, CA
Smoller, BR
Morgan, MB
机构
[1] Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33620 USA
[2] Univ Arkansas Med Sci, Div Dermatopathol, Little Rock, AR 72205 USA
[3] James A Haley Vet Hosp, Dept Pathol, Tampa, FL 33612 USA
关键词
Ets-1; immunohistochemistry; melanocytic nevi; melanoma; TRANSCRIPTION FACTOR; PLASMINOGEN-ACTIVATOR; PROGNOSTIC INDICATOR; TUMOR PROGRESSION; ANGIOGENESIS; MELANOMA; OVEREXPRESSION; VASCULARITY; CARCINOMA; METASTASIS;
D O I
10.1097/01.MP.0000082395.59356.4F
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ets-1 oncoprotein is a transcription factor known to regulate the expression of numerous genes important in extracellular matrix remodeling and angiogenesis. Up-regulation of Ets-1 has been shown to be important in a variety of human malignancies and to correlate with prognosis. To our knowledge, this oncoprotein has not been examined in melanocytic lesions. A series of 10 cutaneous melanomas and 24 benign melanocytic lesions with patient records were independently examined for diagnosis confirmation and immunohistochemical expression by two dermatopathologists. The immunohistochemical expression for Ets-1 (Novocastra, Newcastle upon Tyne, UK) was scored by an average of the mean labeling intensity;, no nuclear staining = 0, weak nuclear staining = 1, moderate = 2, and intense = 3. Ets-1 expression was statistically assessed by the one-way analysis of variance (ANOVA) comparing the mean labeling intensity of melanoma to benign melanocytic nevi. All of the benign melanocytic lesions exhibited negative to weak nuclear staining, with an average mean labeling intensity of 0.4. Melanoma in situ exhibited moderate nuclear staining, for a mean labeling intensity of 2.0, whereas all conventional invasive melanomas exhibited moderate to strong nuclear staining, with a mean labeling intensity of 2.7. Metastatic melanoma exhibited very strong nuclear staining, with a mean labeling intensity of 3.0. Invasive desmoplastic melanoma, like melanoma in situ showed moderate nuclear staining with a mean labeling intensity of 2.1. There was a trend toward more intense staining with melanoma progression. A statistically significant difference in the mean labeling intensity of Ets-1 was seen between invasive melanoma and benign melanocytic nevi (P < .0001). Ets-1 oncoprotein expression, however, does not distinguish among benign melanocytic lesions. Staining intensity and pattern might be a useful adjunct with histomorphology in distinguishing invasive melanoma from benign melanocytic nevi. Furthermore, Ets-1 expression may be an important pathogenic mechanism and predictor of aggressive biologic behavior of cutaneous melanoma, with a trend toward staining intensity increasing as Clark stage increases.
引用
收藏
页码:772 / 777
页数:6
相关论文
共 50 条
  • [31] ETS Proto-Oncogene 1-activated muskelin 1 antisense RNA drives the malignant progression of hepatocellular carcinoma by targeting miR-22-3p to upregulate ETS Proto-Oncogene 1
    Pan, Guozheng
    Zhang, Jian
    You, Faping
    Cui, Tao
    Luo, Peng
    Wang, Shuling
    Li, Xiaomei
    Yuan, Qingzhong
    BIOENGINEERED, 2022, 13 (01) : 1346 - 1358
  • [32] ETS-1 oncoprotein expression and prognosis in melanocytic nevi and cutaneous, melanoma
    Keehn, CA
    Smoller, BR
    Morgan, MB
    MODERN PATHOLOGY, 2003, 16 (01) : 92A - 93A
  • [33] ETS-1 oncoprotein expression and prognosis in melanocytic nevi and cutaneous melanoma
    Keehn, CA
    Smoller, BR
    Morgan, MB
    LABORATORY INVESTIGATION, 2003, 83 (01) : 92A - 93A
  • [34] Ets-1 expression occurs in precancerous colorectal lesions
    Ilyes, A.
    Pap, Z.
    Pavai, Z.
    Mocan, S.
    VIRCHOWS ARCHIV, 2014, 465 : S238 - S239
  • [35] PU.1 regulates the expression of the Vav proto-oncogene
    Denkinger, DJ
    Lambrecht, TQ
    Cushman-Vokoun, AM
    Kawahara, RS
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2002, 84 (04) : 772 - 783
  • [36] Functional interaction between tumor-suppressor p53 and proto-oncogene ets-1 determines the invasive potential of glial tumors
    Todkar, K.
    Hanson, S.
    Schlaffer, S.
    Pawlak, E.
    Tronnier, V.
    Giese, A.
    Kim, E.
    NEURO-ONCOLOGY, 2006, 8 (04) : 318 - 318
  • [37] Proto-oncogene expression in human glomerular diseases
    Takemura, T
    Okada, M
    Akano, N
    Murakami, K
    Hino, S
    Yagi, K
    Takekoshi, Y
    Yoshioka, K
    JOURNAL OF PATHOLOGY, 1996, 178 (03): : 343 - 351
  • [38] Proto-oncogene Ets-1 is pathologically expressed in low-grade astrocytomas and glioblastomas in a tissue and location specific pattern and correlates with patient survival
    Kuhn, Susanne Antje
    Pfeifenbring, Sabine
    Schirrmeister, Anne
    Kratzsch, Tobias
    Traeger, Uwe
    Hanlsch, Uwe Karsten
    Haberl, Hennes
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Cloning and expression of the axolotl proto-oncogene ski
    Ludolph, D. C.
    Neff, A. W.
    Parker, M. A.
    Mescher, A. L.
    B B A - Biomembranes, 1260 (01):
  • [40] Proto-oncogene expression during fracture repair
    Oni, OOA
    INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2000, 31 (05): : 363 - 366